Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma

In advanced-stage hepatocellular carcinoma (HCC), systemic treatment represents the standard therapy. Target therapy has marked a new era based on a greater knowledge of molecular disease signaling. Nonetheless, survival outcomes and long-term response remain unsatisfactory, mostly because of the on...

Descripción completa

Detalles Bibliográficos
Autores principales: Guardascione, Michela, Toffoli, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504231/
https://www.ncbi.nlm.nih.gov/pubmed/32878115
http://dx.doi.org/10.3390/ijms21176302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504231/
https://www.ncbi.nlm.nih.gov/pubmed/32878115
http://dx.doi.org/10.3390/ijms21176302

Ejemplares similares